Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study

被引：2
|
作者：
Wu, Yi-Long [1 ]
Lu, Shun [2 ]
Cheng, Ying [3 ]
Zhou, Caicun [4 ]
Wang, Jie [5 ]
Mok, Tony [6 ]
Zhang, Li [7 ]
Tu, Haiyan [1 ]
Wu, Lin [8 ]
Feng, Jifeng [9 ]
Zhang, Yiping [10 ]
Luft, Alexander Valeriercich [11 ]
Zhou, Jianying [12 ]
Ma, Zhiyong [13 ]
Lu, You [14 ]
Hu, Chengping [15 ]
Shi, Yuankai [16 ,17 ]
Baudelet, Christine [18 ]
Li, Zoe [18 ]
Chang, Jianhua [19 ]
机构：
[1] Guandong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[3] Jilin Canc Hosp, Changchun, Jilin, Peoples R China
[4] Shanghai Pulm Hosp, Shanghai, Peoples R China
[5] Chinese Acad Med Sci, Beijing, Peoples R China
[6] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[7] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
[8] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[9] Jiangsu Canc Hosp, Beijing, Peoples R China
[10] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[11] Leningrad Reg Clin Hosp, St Petersburg, Russia
[12] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Zhejiang, Peoples R China
[13] Henan Canc Hosp, Zhengzhou, Henan, Peoples R China
[14] West China Hosp, Chengdu, Sichuan, Peoples R China
[15] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[16] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
[17] Peking Union Med Coll, Beijing, Peoples R China
[18] Bristol Myers Squibb, Princeton, NJ USA
[19] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT114
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Outcomes of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) in A Regional Australian Population
    Kasherman, Lawrence
    Brungs, Daniel
    Bell, Graeme
    Glasgow, Amanda L.
    Tafreshi, Ali
    Clingan, Philip
    Aghmesheh, Morteza
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 145 - 146
  • [42] Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
    Fehrenbacher, Louis
    von Pawel, Joachim
    Park, Keunchil
    Rittmeyer, Achim
    Gandara, David R.
    Aix, Santiago Ponce
    Han, Ji-Youn
    Gadgeel, Shirish M.
    Hida, Toyoaki
    Cortinovis, Diego L.
    Cobo, Manuel
    Kowalski, Dariusz M.
    De Marinis, Filippo
    Gandhi, Mayank
    Danner, Bradford
    Matheny, Christina
    Kowanetz, Marcin
    He, Pei
    Felizzi, Federico
    Patel, Hina
    Sandler, Alan
    Ballinger, Marcus
    Barlesi, Fabrice
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1156 - 1170
  • [43] Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study
    Wang, Yang
    Hao, Qianyun
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Zhang, Jie
    Chen, Xiaoling
    Ma, Xiangjuan
    Tian, Guangming
    Han, Jindi
    Han, Sen
    Wu, Di
    Long, Jieran
    Zhang, Ziran
    Fang, Jian
    ANTI-CANCER DRUGS, 2024, 35 (05) : 412 - 417
  • [44] Immunotherapy in previously treated non-small cell lung cancer (NSCLC)
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S422 - S432
  • [45] Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)
    Horn, L.
    Brahmer, J.
    Reck, M.
    Borghaei, H.
    Spigel, D. R.
    Steins, M.
    Ready, E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Burgio, M. A.
    Fayette, J.
    Gettinger, S. N.
    Harbison, C. T.
    Li, A.
    Finckenstein, F. G.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 125 - 125
  • [46] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Soria, J. C.
    Bennouna, J.
    Leighl, N.
    Khuri, F.
    Traynor, A. M.
    Johnson, B.
    Kay, A.
    Blais, N.
    Jehl, V.
    Papadimitrakopoulou, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 558 - 559
  • [47] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Leighl, N. B.
    Soria, J.
    Bennouna, J.
    Blais, N.
    Traynor, A. M.
    Papadimitrakopoulou, V.
    Klimovsky, J.
    Jappe, A.
    Jehl, V.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Randomized phase II study of gefitinib alone or with simvastatin in previously treated advanced non-small cell lung cancer (NSCLC)
    Han, J.
    Lee, S.
    Yun, T.
    Moon, Y.
    Park, I.
    Kim, H.
    Lee, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia
    Lu, S.
    Zhang, L.
    Cheng, Y.
    Wang, J.
    Wang, C.
    Wang, M.
    Li, X.
    Wu, Q.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1975 - S1975
  • [50] Nivolumab Experience in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC) in Toledo, Spain
    Martinez Moreno, E.
    Irigoyen Medina, A.
    Martinez Barroso, K.
    Borregon Rivilla, M.
    Alvarez Cabellos, R.
    Cardenas, J. D.
    Andrade Santiago, J.
    Burgueno Lorenzo, I.
    Trujillo Alba, B.
    Chacon Lopez-Muniz, J. I.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2430 - S2430
12345